Takeda to Develop Coronavirus Treatment

Takeda Pharmaceuticals said it will develop a plasma-derived therapy for patients infected with coronavirus.

The drugmaker said it will be developing an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also looking into other products it is developing or marketing that can treat infected patients.

Hyperimmune globulins are plasma derived-therapies that have previously been shown effective for treating severe acute viral respiratory infections.